BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 19, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaitsBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
  • Haisheng Zhang, CEO, Signet

    Signet builds new model for gastric cancer drug discovery

    Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
  • Synergistic antiviral efficacy of HEC-191834 with siRNA in HBV models

  • Captain T Cell raises funds to advance TCR-T pipeline

  • T-knife files CTA for TCR T-cell therapy for solid tumors

  • RVU-305 shows potential against GBM in preclinical studies

  • Signet builds new model for gastric cancer drug discovery

    Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
  • Synergistic antiviral efficacy of HEC-191834 with siRNA in HBV models

    In preclinical studies at Sunshine Lake Pharma Co. Ltd., researchers investigated the antiviral and immune-modulatory potential of HEC-191834, a novel and highly selective human Toll-like receptor 8 (TLR8) agonist, in chronic hepatitis B virus (HBV) models, as well as its activity when combined with siRNA.
  • Captain T Cell raises funds to advance TCR-T pipeline

    Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a best-in-class TCR T-cell therapy targeting MAGE-A4-positive solid tumors and is expected to enter clinical trials in early 2027.
  • T-knife files CTA for TCR T-cell therapy for solid tumors

    T-knife Therapeutics Inc. has filed a clinical trial application (CTA) to initiate a phase I trial of TK-6302, a PRAME-targeted T-cell receptor (TCR) T-cell therapy in solid tumors. Pending CTA approval, the ATLAS trial is planned to begin next year.
  • RVU-305 shows potential against GBM in preclinical studies

    In glioblastoma multiforme, MTAP loss leads to MTA accumulation, which partially inhibits PRMT5, making the cells reliant on residual PRMT5 activity for survival. Targeting this remaining PRMT5 with MTA-cooperative inhibitors induces synthetic lethality, representing a promising targeted approach for MTAP-deleted gliomas. Researchers from Ryvu Therapeutics SA reported the preclinical profile of RVU-305, a PRMT5 inhibitor, in MTAP-deleted cancer models.
  • GSK and Fleming Initiative announce AMR research programs

    GSK plc and the Fleming Initiative have announced six major new research programs to find new ways to slow the progress of antimicrobial resistance (AMR). The Fleming Initiative is a collaboration established by Imperial College London and Imperial College Healthcare NHS Trust to help tackle AMR. Each of the new programs will begin by early next year and are fully funded for 3 years.
  • Samjin Pharmaceutical patents new compounds for MASH

    Samjin Pharmaceutical Co. Ltd. has disclosed inhibitors of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) and/or estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) and/or HSD17B2 (17β-HSD2). As such, they are believed to be potentially useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • Small-molecule p53 Y220C reactivators with enhanced potency presented

    Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1% of solid tumors. Previous research identified a unique, druggable pocket on the p53 surface created by this mutation that constitutes a promising cancer therapeutic target.
  • Scynexis fungerps among funding recipients

    Test tubes, dropper and capsules
  • Inventisbio divulges new WRN inhibitors

  • Idorsia Pharmaceuticals describes new OX2 receptor agonists

  • CEACAM5-targeting ADC with a highly potent pan-RAS(ON) inhibitor payload

    Floating antibody drug conjugates
  • New GTPase KRAS mutant inhibitors disclosed in Adlai Nortye patent

  • Shanghai Phrontline Biopharma discovers new antibody-drug conjugates

  • Targeting P-gp to inhibit drug efflux, autophagic flux in breast cancer

    Breast cancer cells.
  • NME Digest Series

Sponsored content

Conferences

  • 3D illustration of cancer in crosshairs

    AB-801 enhances KRAS inhibitor antitumor activity

    AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
    Researchers from Arcus Biosciences Inc. described the antitumor efficacy of AB-801, an AXL inhibitor in several cancer models.
  • Art concept for tumor

    Immuneonco’s IMM-2510 shows promise for solid tumors

    Society for Immunotherapy of Cancer
    The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not all patients respond to therapy or respond for short duration. IMM-2510 is a novel bispecific antibody developed by Immuneonco Biopharmaceuticals Inc. that targets both PD-L1...
  • Johns Hopkins reports work on gene therapy for ADPKD

    Nephrology
    Developing new gene therapies for autosomal dominant polycystic kidney disease (ADPKD) is still a challenge to date. A group of researchers from the Johns Hopkins Medicine in Baltimore has presented results from evaluation of a new gene therapy for treating ADPKD, AAV1-CBdelta27-264CFTR, where they...
  • Tango’s first-in-class CoREST inhibitor overcomes anti-PD-1 resistance

    Society for Immunotherapy of Cancer
    Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, designed to treat immunotherapy-resistant STK11-mutant tumors.
More in Conferences

Today's news in brief

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • Pretzel Therapeutics discovers new POLG modulators

  • New PTPN2/PTP1B degraders disclosed in Northridge Health patent

  • Circle Pharma describes new CDK inhibitors

  • Assembly Biosciences divulges new viral replication inhibitors

  • Imhotex patents new NOD2 activators for Crohn’s disease

  • Novartis discovers new HER2-targeting peptide-drug conjugates

  • New GIPR antagonists disclosed in Pfizer patent

  • Abbvie describes new LPAR1 antagonists

  • Nanjing Zaiming Pharmaceutical divulges new WRN inhibitors

  • Shouyao patents new MALT1 inhibitors

Cancer

  • Microbiome illustration

    ‘Most complete’ map of oral microbiome enables links to systemic disease

    Artificial intelligence
    South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable...
  • Novel bis-heterocyclic PRMT inhibitors against TNBC

    New compound
  • CDK2 degraders show activity in HR+/HER2- and CCNE1-amplified breast tumors

    Conferences
  • Macrocyclic KIF18A inhibitors show preclinical promise

    Conferences
  • Charm nominates CHM-029 as development candidate for AML

More in Cancer

Infection

  • Anti-malarial targets P. falciparum phosphatidylinositol 4-kinase with reduced toxicity

    In an effort to generate an effective and safer inhibitor, researchers at the University of Cape Town, University of Dundee and Massachusetts Institute of Technology used structure-guided rational design to improve on their previously reported 2,8-diaryl-1,5-naphthyridine inhibitor.
  • Dual-antigen mRNA vaccine protects against lethal DBV challenge

    Immune
    Investigators from the University of Science and Technology of China and RNAlfa Biotech have described a novel mRNA-based vaccine candidate against Dabie Banda virus (DBV), which has fatality rates of up to 30% in some East Asian countries.
  • ‘Most complete’ map of oral microbiome enables links to systemic disease

    Science
    South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable...
  • Aligos and KU Leuven divulge new antivirals

    Coronavirus
  • Agents for Acinetobacter infections named in Chinese Academy of Medical Sciences patent

    Patents
  • Small molecules targeting ClpX to combat MRSA

  • Designing broad-spectrum antivirals against AAK1

More in Infection

Neurology/psychiatric

  • Amyloid plaques on nerve cell

    Akeso’s AK-152 gains IND clearance in China for Alzheimer’s

    Regulatory
    Akeso Inc. has received clearance from China’s National Medical Products Administration (NMPA) to initiate clinical trials with AK-152 for Alzheimer’s disease.
  • Man pulling back clouds for sunshine

    Adenosine surge is common thread in ketamine and ECT response

    Science
    Researchers from the Chinese Institute for Brain Research, the Chinese Academy of Medical Sciences, and their collaborators have identified adenosine as the driving force behind the rapid, fast-acting antidepressant effects of ketamine and electroconvulsive therapy (ECT). “Our journey into this...
  • Shanghai Innoxtal Therapeutics patents new Nav1.8 blockers

    Patents
    Shanghai Innoxtal Therapeutics Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia and urinary incontinence.
  • Drosophila melanogaster (fruit fly) on a blade of grass

    Drosophila genetic screening reveals mechanisms behind AD pathology

    Researchers from the Baylor College of Medicine have characterized 100 conserved Alzheimer’s disease (AD) risk orthologue genes in Drosophila and found several with unknown roles in brain structure, function and stress resilience. The implication of this finding is that new pathways of...
  • Brain with handshake and cityscape

    Transition Bio and Voyager Therapeutics partner in ALS and FTD

    Collaboration
    Transition Bio Inc. and Voyager Therapeutics Inc. have entered into a drug discovery collaboration and license option agreement for novel, selective small molecules for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology.
More in Neurology/psychiatric

Immune

  • ‘Encyclopedia’ of xenotransplantation reveals drivers of immune rejection

  • QEL-005 restores homeostasis in inflammatory disorders

  • NKX-019 induces CD19 depletion in autoimmune disease

  • Commit Biologics’ complement engager platform studied in NHPs

  • Inje University discovers new PDPK1 inhibitors

  • Azalea exits stealth to develop its in vivo gene engineering technology

  • CDR-Life’s new dual-targeting T-cell engager

  • Microglia acting like T cells mitigate Alzheimer’s progression

  • Pentacyclic derivatives for autoimmune diseases disclosed in Hansoh patent

  • Boehringer Ingelheim licenses CDR-Life’s CDR-111

Endocrine/metabolic

  • Illustration of adipose tissue under the skin

    Mitorx Therapeutics raises funds to advance Myo-004 for obesity

    Financings
    Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead mitochondrial-targeted program, Myo-004, through clinical candidate selection.
  • Century Therapeutics unveils β islet program for type 1 diabetes

  • CGX-926 corrects MC4R deficiency-driven obesity

    Conferences
  • 35pharma’s HS-235 as new approach for obesity treatment

    Conferences
  • Korro Bio nominates KRRO-121 as development candidate

    Gastrointestinal
More in Endocrine/metabolic

Biomarkers

  • Art concept for medical research

    With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

    Neurology/psychiatric
    Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical settings. Many individual studies as well as large projects like the Psychiatric Ratings using Intermediate Markers (PRISM) studies and the...
  • Anchoring, and bootstrapping, psychiatry into the precision medicine era

    Neurology/psychiatric
    Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are working on improving diagnoses by investigating potential biomarkers and collection methods.
  • Biomarker panel of three serum microRNAs predicts cervical cancer prognosis

    Cancer
    MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis. Because their expression patterns differ across tumor types and stages, miRNA profiles hold strong potential as noninvasive diagnostic and...
  • LINC01354 is a prognostic marker in esophageal cancer

    Cancer
  • FGF5 gene involved in excessive hair growth

    Conferences
  • Study identifies REST as biomarker and siRNA target in ALS

    Neurology/psychiatric
  • New link between PRRX1 gene and open-angle glaucoma

    Conferences
More in Biomarkers

Gastrointestinal

  • Numab and Kaken sign agreement for NM-81 for IBD

    Collaboration
    Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have entered into a strategic licensing and co-development agreement for NM-81, a multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
  • Genfit and Everzom form research collaboration in liver failure

    Collaboration
    Genfit SA has established a research collaboration with Everzom SAS to expand its acute-on-chronic liver failure (ACLF) research via exosome-based regenerative technology. The partners plan to conduct exploratory studies to assess efficacy of...
  • Eilean presents in vivo data on MALT1 degrader TE-205

    Degradation inducer
    Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis.
  • Interline Therapeutics patent reports RIPK2 inhibitors for IBD

    Patents
    Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
  • Daewon Pharm patent reveals new H+/K+-ATPase inhibitors

    Patents
    Daewon Pharmaceutical Co. Ltd. has reported new compounds acting as H+/K+-ATPase inhibitors useful for the treatment of reflux esophagitis.
  • Proqr’s AX-0810 gains European clinical trial clearance

    Regulatory
    Proqr Therapeutics NV has received clinical trial application (CTA) authorization under the EMA’s new centralized review process for a phase I study of AX-0810, which is being developed for the treatment of cholestatic diseases such as primary...
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • Esperion Therapeutics CEO Sheldon Koenig
  • Trying this at home: Bioxcel steps closer to an sNDA for Igalmi
  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, BioWorld Science and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing